Health Score

0 Good

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 142 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact142 DOIs

Deposit reference lists for 136 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact136 DOIs

Add abstracts to 20 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact20 DOIs

DOIs for this ISSN

Showing the top 5 of 197 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Tactical Combat Casualty Care: Guidelines for Medical Person… (10.32902/2663-0338-2022-2-42-49)	References ORCID	34.95	4
2	Аналіз видів резистентності МБТ у дітей зі вперше діагностов… (10.32902/2663-0338-2022-4.1-08)	References ORCID	15.05	1
3	Особливості контактів у хворих на туберкульоз дітей (10.32902/2663-0338-2022-4.1-09)	References ORCID	15.05	1
4	Відомі механізми формування медикаментозної стійкості M. tub… (10.32902/2663-0338-2022-4.1-15)	References ORCID	15.05	1
5	Перебіг туберкульозу легень на тлі коронавірусної інфекції з… (10.32902/2663-0338-2022-4.1-21)	References ORCID	15.05	1
6	Tuberculosis: fasten your seat belts, we are entering a turb… (10.32902/2663-0338-2022-2-5-7)	ORCID	11.93	2
7	Determination of the effectiveness of short-term nebulizer t… (10.32902/2663-0338-2022-2-21-28)	ORCID	7.53	1
8	Forecasting thrombotic complications in patients with commun… (10.32902/2663-0338-2021-3-12-17)		0.00	2
9	Dynamics of the incidence of the relapses in patients with p… (10.32902/2663-0338-2021-3-18-24)		0.00	0
10	The impact of the COVID-19 pandemic on the financial sector… (10.32902/2663-0338-2021-3-25-29)	ORCID	0.00	0
11	The problem of hypersensitivity to vitamin preparations (10.32902/2663-0338-2021-3-30-39)		0.00	3
12	Diagnosis of disappearing lung syndrome as a complication of… (10.32902/2663-0338-2021-3-5-11)		0.00	2
13	Diagnostics of lesions of parenchymatic organs in COVID-19 w… (10.32902/2663-0338-2021-4-16-24)		0.00	3
14	Laboratory evaluation of the efficacy of Liastene applicatio… (10.32902/2663-0338-2021-4-25-31)		0.00	0
15	Risks of using pre-event time scale and ordinal scale measur… (10.32902/2663-0338-2021-4-32-37)		0.00	0
16	The role of vitamin D deficiency in antituberculous protecti… (10.32902/2663-0338-2021-4-38-44)		0.00	3
17	Inhaled antiseptics and inhaled antiviral non-prescription d… (10.32902/2663-0338-2021-4-5-15)		0.00	0
18	Determination of dynamics and stage of development of COVID-… (10.32902/2663-0338-2022-1-16-22)		0.00	1
19	Pathogenetic treatment of patients with COVID-19 at the outp… (10.32902/2663-0338-2022-1-23-31)		0.00	1
20	Endothelium is the main target of coronavirus infection (10.32902/2663-0338-2022-1-32-39)		0.00	1
21	Clinical case of concomitant tuberculosis and COVID-19 on th… (10.32902/2663-0338-2022-1-40-46)		0.00	0
22	Invest to end tuberculosis. Save a life (10.32902/2663-0338-2022-1-5-6)	References	0.00	0
23	Lung lever after COVID-19: clinical-X-ray, surgical and morp… (10.32902/2663-0338-2022-1-7-15)		0.00	2
24	The first data on international multicenter clinical study R… (10.32902/2663-0338-2022-2-11-20)		0.00	0
25	Impact of pharmacotherapy with tiotropium/olodaterol on the… (10.32902/2663-0338-2022-2-29-34)		0.00	0
26	Capillary leak syndrome in patients with endogenous intoxica… (10.32902/2663-0338-2022-2-35-41)		0.00	0
27	Chemosynthesis: a history of innovation (10.32902/2663-0338-2022-2-50-56)		0.00	0
28	Clinical case of tuberculous pleurisy in sarcoidosis patient (10.32902/2663-0338-2022-2-8-10)		0.00	0
29	Modern algorithms of geno-phenotypic diagnosis of tuberculos… (10.32902/2663-0338-2022-3-13-20)		0.00	0
30	The effect of L-arginine and L-carnitine preparations on the… (10.32902/2663-0338-2022-3-21-25)		0.00	1
31	Differential diagnosis of the complicated course of COVID-19… (10.32902/2663-0338-2022-3-26-34)		0.00	0
32	Changes in immunological reactivity of patients with pulmona… (10.32902/2663-0338-2022-3-35-41)		0.00	2
33	Management of patients with allergic diseases during pregnan… (10.32902/2663-0338-2022-3-42-53)		0.00	0
34	Antiviral activity of aminocaproic acid against SARS-CoV-2:… (10.32902/2663-0338-2022-3-5-12)		0.00	1
35	Serhiy Winogradsky – a great Ukrainian (10.32902/2663-0338-2022-3-57-64)		0.00	0
36	Morbidity and mortality during wars and armed conflicts: tre… (10.32902/2663-0338-2022-4-14-19)		0.00	8
37	Infectious complications of the respiratory tract and lungs… (10.32902/2663-0338-2022-4-20-29)		0.00	5
38	Application of the RELATIVE scheme in the program of treatme… (10.32902/2663-0338-2022-4-30-34)		0.00	0
39	Analysis of antibacterials for systemic use recommended for… (10.32902/2663-0338-2022-4-35-45)		0.00	1
40	Features of the influence of degenerative changes of the cer… (10.32902/2663-0338-2022-4-46-51)		0.00	0
41	Treatment of MDR-TB/HIV/CMV patients under individualized re… (10.32902/2663-0338-2022-4-52-58)		0.00	0
42	Regenerative medicine: going beyond transplantology (10.32902/2663-0338-2022-4-6-13)		0.00	0
43	Безпосередні та віддалені результати першого впровадження ре… (10.32902/2663-0338-2022-4.1-01)	References ORCID	0.00	0
44	Попередні результати різних за складом і тривалістю модифіко… (10.32902/2663-0338-2022-4.1-02)	References ORCID	0.00	0
45	Результати діяльності Центру дитячої фтизіохірургії ДУ «Наці… (10.32902/2663-0338-2022-4.1-03)	References ORCID	0.00	0
46	Хірургічне лікування множинної лікарської стійкості туберкул… (10.32902/2663-0338-2022-4.1-04)	References ORCID	0.00	0
47	Визначення оптимальних термінів для хірургічного лікування х… (10.32902/2663-0338-2022-4.1-05)	References ORCID	0.00	0
48	Сучасні аспекти лабораторної діагностики легеневого туберкул… (10.32902/2663-0338-2022-4.1-06)	References ORCID	0.00	0
49	Захворюваність на туберкульоз у дітей і підлітків в Україні… (10.32902/2663-0338-2022-4.1-07)	References ORCID	0.00	0
50	Туберкульоз і COVID-19: що очікувати лікарям України? (10.32902/2663-0338-2022-4.1-10)	References ORCID	0.00	0